Cancer-Derived Immunoglobulin G and Pancreatic Cancer
- 6 July 2024
- book chapter
- Published by Springer Nature
- Vol. 1445, 129-135
Abstract
Immunoglobulin (Ig) is traditionally believed to be produced solely by B cells. Nonetheless, mounting evidence has demonstrated that various types of Igs are extensively expressed in many cell types. Among them, IgG is found to be highly expressed in cancer cells and is thus labeled as cancer-derived IgG. Cancer-derived IgG shares identical fundamental structures with B cell-derived IgG, but displays several unique characteristics, including restricted variable region sequences and unique glycosylation modifications for those expressed by epithelial cancers. Cancer-derived IgG plays multiple crucial roles in carcinogenesis, including facilitating cancer invasion and metastasis, enhancing cancer stemness, contributing to chemoresistance, and remodeling the tumour microenvironment. Recent studies have discovered that cancer-derived sialylated IgG (SIA-IgG) is extensively expressed in pancreatic cancer cells and is predominantly located in the cytoplasm and on the cell membrane. Cancer-derived IgG expressed by pancreatic cancer presents a restrictive variable region sequence and contains a unique sialylation site of the Fab region. Functionally, cancer-derived IgG participates in pancreatic cancer progression via different mechanisms, such as promoting proliferation, facilitating migration and invasion, resisting apoptosis, inducing inflammation, and modulating the tumour microenvironment. SIA-IgG has shown potential as a clinical biomarker. The expression of SIA-IgG is associated with poor tumour differentiation, metastasis, and chemoresistance in pancreatic cancer. High expression of SIA-IgG can serve as an independent prognostic factor for pancreatic cancer. Additionally, SIA-IgG expression elevated with malignant progression for the precursor lesions of pancreatic cancer. These findings present a prospect of applying cancer-derived IgG as a novel diagnostic and therapeutic target in the management of pancreatic cancer, and aiding in overcoming the challenge in the treatment of this stubborn malignancy.Keywords
This publication has 30 references indexed in Scilit:
- Pancreatic cancerThe Lancet, 2020
- The tumour microenvironment in pancreatic cancer — clinical challenges and opportunitiesNature Reviews Clinical Oncology, 2020
- Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cellsCellular & Molecular Immunology, 2019
- Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophagesBritish Journal of Cancer, 2019
- Lung squamous cell carcinoma cells express non-canonically glycosylated IgG that activates integrin-FAK signalingCancer Letters, 2018
- Cancer-derived immunoglobulin G promotes tumor cell growth and proliferation through inducing production of reactive oxygen speciesCell Death & Disease, 2013
- Immunoglobulin gamma heavy chain gene with somatic hypermutation is frequently expressed in acute myeloid leukemiaLeukemia, 2012
- Immunoglobulin G is present in a wide variety of soft tissue tumors and correlates well with proliferation markers and tumor gradesCancer, 2010
- Expression and secretion of immunoglobulin alpha heavy chain with diverse VDJ recombinations by human epithelial cancer cellsMolecular Immunology, 2007
- Expression of heavy-chain constant region of immunoglobulin and T-cell receptor gene transcripts in human non-hematopoietic tumor cell linesGenes, Chromosomes and Cancer, 1998